Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-09 4:10 pm Purchase |
2025-04-02 | 13G | Beta Bionics, Inc. BBNX |
Sands Capital Life Sciences Pulse Fund II. L.P. | 3,154,409 7.300% |
3,154,409 (New Position) |
Filing History |
| 2024-10-25 5:50 pm Purchase |
2024-10-21 | 13G | Inhibikase Therapeutics, Inc. IKT |
Sands Capital Life Sciences Pulse Fund II. L.P. | 10,950,000 16.300% |
10,950,000 (New Position) |
Filing History |
| 2023-06-22 4:32 pm Sale |
2023-06-20 | 13D | DICE Therapeutics, Inc. DICE |
Sands Capital Life Sciences Pulse Fund II. L.P. | 1,886,470 4.000% |
-1,262,500 (-40.09%) |
Filing History |
| 2022-11-25 4:25 pm Purchase |
2022-11-15 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Sands Capital Life Sciences Pulse Fund II. L.P. | 1,652,606 7.900% |
1,652,606 (New Position) |
Filing History |
| 2021-09-24 6:12 pm Purchase |
2021-09-17 | 13D | DICE Therapeutics, Inc. DICE |
Sands Capital Life Sciences Pulse Fund II. L.P. | 3,148,970 8.700% |
3,148,970 (New Position) |
Filing History |